Phase III randomized pilot study comparing interferon α- 2b in combination with radiation therapy versus radiation therapy alone in patients with stage III-B carcinoma of the cervix

International Journal of Gynecological Cancer

Volumn 13, Issue 2, 2003, Pages 164-169

  Yazigi, Roberto ^a,b   Aliste, G ^a   Torres, R ^b   Ciudad, A M ^b   Cuevas, M ^b   Garrido, J ^b   Prado, S ^b   Sola A ^b   Castillo, R ^b   Cerda, B ^b   Cumsille, M A ^c   Gonzalez, M ^b   Navarro, C ^b   Reyes, J M ^a  

^a CLÍNICA LAS CONDES   (Chile)

^b National Cancer Institute   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

Author keywords

Cervix; Interferon 2b; Radiation therapy; Squamous cell carcinoma; Stage IIIB

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; CISPLATIN; ISOTRETINOIN; RETINOIC ACID; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DEATH; DIARRHEA; DISEASE COURSE; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MEDICAL EXAMINATION; MULTIMODALITY CANCER THERAPY; PELVIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URETER OBSTRUCTION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY; ADJUVANT THERAPY; AGED; CHILE; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; PATHOLOGY; PILOT STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL; TUMOR RECURRENCE; UTERINE CERVIX TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHILE; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTERFERON ALFA-2B; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PILOT PROJECTS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 0037631583     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2003.13031.x     Document Type: Article

References (29)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide frequency of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.
2. Grenlee RT, Murrey T, Bolden S, Wingo PA. Cancer statistics 2000. CA Cancer J Clin 2000;50:7-33.
3. Whitney CW, Sause W, Bundy BN et al. A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17:1339-134.
4. Morris M, Eifel PJ, Lu J et al. Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high risk cervical cancer: a randomized Radiation Therapy Oncology Group clinical trial. N Engl J Med 1999;340:1137-43.
5. Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatin-based chemoradiation improves progression free and overall survival in advancer cervical cancer: Results of a randomized Gynecologic Oncology Group study. N Engl J Med 1999;340:1144-53.
6. Peters WA III, Liu PY, Barrett RJ et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-13.
7. Keys HM, Bundy BM, Stehman FB et al. A comparison of weekly cisplatin during radiation therapy versus irradiation alone each followed by adjuvant hysterectomy in bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. N Eng J Med 1999;340:1154-61.
8. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Pecorelli S, Parham GP. Effects of retinoic acid combined with Interferon-γ on the expression of a tumor rejection antigen (heat shock protein gp96) in human cervical cancer. Int J Gynecol Cancer 1998;8:158-63.
9. Massad LS, Turyk ME, Bitterman P, Wilbanks GD. Interferon-α and all-trans-retinoic acid reversibly inhibit the in vitro proliferation of cell lines derived from cervical cancers. Gynecol Oncol 1996;60:428-34.
10. Angioli R, Sevin BU, Perras JP et al. In vitro potentiation of radiation cytotoxicity by recombinant Interferons in cervical cancer cell lines. Cancer 1993;71:3717-25.
11. Kardamakis D, Gillies NE, Souhami RL, Bewerley PCL. Recombinant human Interferon alpha-2b enhances the radiosensitivity of small cell lung cancer in vitro. Anticancer Res 1989;9:1041-4.
12. Dritschlio A, Mossman K, Gray M, Sreevalean T. Potentiation of radiation injury by Interferon. Am J Oncol (CCT) 1982;5:79-82.
13. Kaplan E, Meier P. Non-parametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457-81.
14. Ryu S, Kim OB, Kim SH, He SQ, Kim JH. In vitro radiosensitization of human cervical carcinoma cells by combined use of 13-cis-retinoic acid and Interferon-alpha2a. Int J Radiat Oncol Biol Phys 1998;41:869-73.
15. Creasey AA, Bartholomew JC, Merigan TC. Role of G0-G1 arrest in the inhibition of tumor cell growth by Interferon. Proc Natl Acad Sci USA 1980;77:1471-5.
16. Toma S, Ragni N, Raffo P et al. Efficacy of the association of 13-cis-retinoic acid (13cRA) and alpha-Interferon 2a (alpha-IFN 2a) in moderate-severe cervical intraepithelial neoplasia (CIN II-III): a pilot study. Anticancer Res 1996;16:931-6.
17. Rotola A, Costa S, Di Luca D et al. Beta-Interferon treatment of cervical intraepithelial neoplasia: a multicenter clinical trial. Intervirology 1995;38:325-31.
18. De Aloysio D, Miliffi L, Iannicelli T, Penacchioni P, Bottiglioni F. Intramuscular Interferon-beta treatment of cervical intraepithelial neoplasia II associated with human papillomavirus infection. Acta Obstet Gynecol Scand 1994;73:420-4.
19. Lippman SM, Kavanagh JJ, Paredes Espinoza M et al. 13 cis-retinoic acid plus Interferon alpha-2a, highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992;84:241-5.
20. Gonzalez Léon C, Lippman SM, Kudelka AP, Edwards CL, Kavanagh JJ. Phase II study of cisplatin, 5-fluorouracil and Interferon-alpha in recurrent carcinoma of the cervix. Invest New Drugs 1995;13:73-6.
21. Weiss GR, Liu PY, Alberts DS et al. 13-cis-retinoic acid or all-trans-retinoic acid plus Interferon-α in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trial. Gynecol Oncol 1998;71:386-90.
22. Wadler S, Schwartz EL, Haynes H et al. All-trans retinoic acid and Interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group. Cancer, 1997;79:1574-80.
23. Look KY, Blessing JA, Nelson BE, Johnson GA, Fowler WC Jr, Reid GC. A phase II trial of isotretinoin and alpha Interferon in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 1998;21:591-4.
24. Park TK, Lee JP, Kim SN, Choi AP, Kudelka AP, Kavanagh JJ. Interferon-α2a, 13-cis-retinoic acid and radiotherapy for locally advanced carcinoma of the cervix: a pilot study. Eur J Gynaecol Oncol 1998;19:35-8.
25. Verastegui-Aviles E, Mohar A, Mota A, Guadarrama A, De la Garza-Salazar J. Combination of radiation therapy and Interferon α-2b in patients with advanced cervical carcinoma: a pilot study. Int J Gynecol Cancer 1999;9: 401-5.
26. Stock RG, Dottino P, Scott Jennings T et al. Enhanced radiosensitization with Interferon-α-2b and cisplatin in the treatment of locally advanced cervical carcinoma. Gynecol Oncol 1997;67:309-15.
27. Kavanagh JJ, Lippman SM, Paredes-Espinoza M et al. The combination of 13-cis-retinoic acid and Interferon-α2a with radiation therapy in squamous cell carcinoma of the cervix. Int J Gynecol Cancer 1996;6:439-44.
28. Piver MS, Barlow JJ, Vongtama V et al. Hydroxyurea. A radiation potentiator in carcinoma of the uterine cervix. Am J Obstet Gynecol 1983;147:803-8.
29. Hreshchyshyn MM, Aron BS, Boronow RC et al. Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. Int J Radiat Oncol Biol Phys 1979;56:317-22.